Cedazuridine
Inaqovi, Inqovi (cedazuridine) is a small molecule pharmaceutical. Cedazuridine was first approved as Inqovi on 2020-07-07. It has been approved in Europe to treat myeloid leukemia. It is known to target cytidine deaminase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Inqovi
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| inqovi | New Drug Application | 2022-05-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| myelodysplastic syndromes | — | D009190 | D46 |
| myeloid leukemia | — | D007951 | C92 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CEDAZURIDINE / DECITABINE, INQOVI, OTSUKA | |||
| 2027-07-07 | ODE-316 | ||
| 2025-07-07 | NCE | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
65 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 21 | 19 | 3 | — | — | 31 |
| Leukemia | D007938 | — | C95 | 18 | 17 | 3 | — | — | 29 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 19 | 15 | 3 | — | — | 28 |
| Preleukemia | D011289 | — | — | 17 | 17 | 3 | — | — | 26 |
| Myeloid leukemia | D007951 | — | C92 | 16 | 14 | 3 | — | — | 25 |
| Syndrome | D013577 | — | — | 14 | 16 | 3 | — | — | 22 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 6 | 4 | 2 | — | — | 11 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 6 | 4 | 2 | — | — | 11 |
| Myelomonocytic leukemia acute | D015479 | — | C92.5 | 1 | 3 | 1 | — | — | 4 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 2 | 1 | — | — | 2 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 4 | 4 | — | — | — | 7 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 2 | 3 | — | — | — | 4 |
| Recurrence | D012008 | — | — | 3 | 2 | — | — | — | 4 |
| Prostatic neoplasms | D011471 | — | C61 | 3 | 1 | — | — | — | 3 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 3 | 1 | — | — | — | 3 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 1 | 1 | — | — | — | 2 |
| Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | — | — | 2 |
| Chondrosarcoma | D002813 | — | — | — | 1 | — | — | — | 1 |
| Residual neoplasm | D018365 | — | — | 1 | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | — | 2 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | — | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | 2 | — | — | — | — | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
| T-cell leukemia | D015458 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | — | 1 |
Show 9 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cedazuridine |
| INN | cedazuridine |
| Description | Decitabine/cedazuridine, sold under the brand name Inqovi among others, is a fixed-dose combination anticancer medication used for the treatment of adults with myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML). It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor.
|
| Classification | Small molecule |
| Drug class | antivirals; antineoplastics (uridine derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F |
Identifiers
| PDB | — |
| CAS-ID | 1141397-80-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3237547 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 39IS23Q1EW (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 327 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
915 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use